[Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases]

Clicks: 438
ID: 110968
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #2 of 18 articles by views in Wiadomosci lekarskie (Warsaw, Poland : 1960)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Remission in connective tissue diseases became a realistic goal of therapy nowadays. However, there is lack of recommendations on the management after achieving a remission. Chronic exposure to immunosuppressive or immunomodulatory drugs may be associated with adverse events, that is why temporal wi …
Reference Key
b2015wiadomosci[discontinuation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Targońska-Stępniak B;;
Journal Wiadomosci lekarskie (Warsaw, Poland : 1960)
Year 2015
DOI
DOI not found
URL
https://www.pubmed.gov/26753211/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine English Abstract Bozena Targońska-Stepniak pmid:26753211 Connective Tissue Diseases / drug therapy* Drug Administration Schedule Immunomodulation* Immunosuppressive Agents / administration & dosage* Immunosuppressive Agents / adverse effects Recurrence Remission Induction Withholding Treatment*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.